Last updated: September 2, 2026
Lorecivivint is an investigational, intra-articular small-molecule therapy for knee osteoarthritis developed by Biosplice Therapeutics, formerly Samumed. The program has reached Phase 3 but has not received FDA approval, has no Orange Book listing, and has no publicly disclosed commercial launch date. Its investment case depends on resolving inconsistent Phase 3 efficacy results and proving that a disease-modifying or durable-treatment profile can support premium pricing against low-cost injections and established analgesics.
The base-case commercial outlook is a limited-to-moderate launch followed by peak annual sales of approximately $500 million to $1.2 billion in the United States and major developed markets. A successful disease-modifying label and annual or less-frequent dosing could support peak sales above $1.5 billion. The risk-adjusted value is materially lower because the program has not established a consistent pivotal-trial benefit or reached regulatory review.
What is the development status of lorecivivint?
As of June 2024, lorecivivint remained an unapproved Phase 3 osteoarthritis candidate. The drug is also known as SM04690 and was developed by Samumed, which later changed its corporate name to Biosplice Therapeutics.
Lorecivivint is designed for intra-articular administration into the knee. Its proposed mechanism involves modulation of the Wnt signaling pathway through inhibition of CLK2 and DYRK1A activity. Wnt signaling is implicated in cartilage degradation, synovial inflammation, and osteoarthritis disease progression.
| Development item |
Status |
| Active ingredient |
Lorecivivint, also known as SM04690 |
| Developer |
Biosplice Therapeutics, formerly Samumed |
| Administration |
Intra-articular knee injection |
| Lead indication |
Moderate-to-severe knee osteoarthritis |
| Regulatory status |
Investigational; not FDA approved |
| Clinical stage |
Phase 3 |
| FDA NDA |
No publicly disclosed application |
| Orange Book |
No listing |
| Commercial partner |
No publicly disclosed global commercialization partner |
| Biosimilar pathway |
Not applicable |
The development program has focused on single-injection treatment and durable improvements in pain, function, and structural disease measures. The commercial premise is stronger than that of conventional corticosteroids or hyaluronic acid if lorecivivint can demonstrate durable clinical benefit with infrequent dosing.
Which Phase 3 trials tested lorecivivint?
The principal pivotal studies were JOINT 1 and JOINT 2, which evaluated a single intra-articular injection in patients with knee osteoarthritis.
| Trial |
Registry |
Approximate enrollment |
Dose |
Primary focus |
| JOINT 1 |
NCT03065246 |
More than 700 patients |
12 mg |
Knee pain and function |
| JOINT 2 |
NCT03928184 |
Nearly 700 patients |
12 mg |
Confirmatory efficacy |
| Phase 2b program |
Various studies |
Several hundred patients |
Multiple doses |
Pain, function, and structural outcomes |
Public disclosures indicated that JOINT 1 produced a statistically significant improvement in the prespecified pain endpoint at one year, while JOINT 2 did not reproduce the same result on its primary endpoint. That inconsistency materially weakened the program’s regulatory position.
The company continued to evaluate responder subgroups and other clinical measures, including patients with more advanced disease and those with specific imaging or biomarker characteristics. Regulatory approval would generally require a reproducible benefit on clinically meaningful endpoints, not only post hoc subgroup findings.
When could lorecivivint reach the market?
No public FDA approval date or commercial launch date had been established by June 2024. The program would likely require one of two paths:
- A new or additional pivotal study producing consistent efficacy results.
- A regulatory submission based on existing studies, supported by subgroup analyses and additional evidence.
The second path would carry substantial review risk because the primary Phase 3 results were not consistently positive. If an additional pivotal study began after 2024, U.S. approval would likely be several years away. A conventional sequence would include protocol finalization, patient recruitment, one-year follow-up, database lock, NDA preparation, FDA review, and commercial scale-up.
| Milestone |
Earliest practical timing under a successful restart scenario |
| New pivotal trial initiation |
2024-2025 |
| Trial completion and database lock |
2026-2027 |
| NDA submission |
2027-2028 |
| FDA action |
2028-2029 |
| Potential launch |
2028-2029 |
These dates represent a development scenario rather than a disclosed company timeline.
What is the FDA regulatory status of lorecivivint?
Lorecivivint is not FDA approved. It has no approved label, no FDA-granted market exclusivity, and no Orange Book patent entries.
Because the product is a novel small molecule administered by intra-articular injection, the expected regulatory pathway would be a new drug application rather than a biologics license application. Biosimilar approval rules would not apply. After approval, a follow-on product could potentially pursue an abbreviated pathway, but the complexity of injectable formulation, injection-site performance, manufacturing controls, and clinical endpoint requirements could make a 505(b)(2) or other hybrid strategy more relevant than a conventional immediate-release ANDA.
No publicly disclosed Paragraph IV certification, ANDA litigation, or FDA patent dispute involving lorecivivint was identified through June 2024. Paragraph IV exposure would become commercially relevant only after an approved reference product and Orange Book-listed patents exist.
What patents protect lorecivivint?
The program’s protection is expected to rely on a combination of composition-of-matter, method-of-use, formulation, dosing, and manufacturing patents. Public company materials have described a broad intellectual-property estate around Wnt-pathway modulators and osteoarthritis treatment, but an authoritative current patent expiration schedule for the lorecivivint commercial product was not publicly established by June 2024.
The relevant patent categories are:
Composition-of-matter patents
These patents cover the chemical structure of lorecivivint and related kinase-modulating compounds. Composition claims generally provide the strongest protection if the exact active ingredient is covered and the patent remains enforceable.
Method-of-use patents
Potential claims include treatment of knee osteoarthritis, reduction of pain or stiffness, improvement of joint function, protection of cartilage, and use in defined patient populations. Method-of-use patents can be important where composition claims expire earlier, although enforcement against a generic depends on the approved label and prescribing behavior.
Formulation and delivery patents
The product’s intra-articular formulation may support claims covering:
- Concentration and dose volume
- Suspension or solution characteristics
- Excipients and stabilizers
- Injection-site tolerability
- Extended retention in the joint
- Single-dose or repeat-dose regimens
Formulation patents may create a meaningful barrier if competitors cannot replicate the same injection profile without infringing or conducting additional clinical work.
Manufacturing patents
Manufacturing protection may cover synthesis intermediates, purification, particle-size control, sterile filling, and injectable product specifications. These rights are secondary to composition patents but can complicate generic development and technology transfer.
A full exclusivity analysis requires confirmation of issued patent numbers, terminal disclaimers, patent-term adjustment, patent-term extension eligibility, and the final commercial formulation. No such Orange Book-based schedule exists before approval.
How strong is the patent estate for lorecivivint?
The patent estate appears strategically useful but cannot yet be valued like the estate of an approved product. The strongest potential protection would come from an unexpired composition patent paired with formulation and method-of-use claims. The absence of an approved label means the commercial enforceability of method-of-use patents has not been tested in litigation.
Patent strength is currently constrained by four factors:
- The product has no FDA-approved formulation.
- No Orange Book listing establishes the patents that would be certified against by ANDA applicants.
- Clinical and regulatory uncertainty reduces the practical value of long-dated patent rights.
- Intra-articular competitors may use different active ingredients and avoid direct patent infringement.
No publicly disclosed settlement agreement, patent-license transaction, or major patent litigation involving lorecivivint was identified through June 2024. Biosplice remained the principal publicly identified developer and rights holder.
What competitive products could limit lorecivivint sales?
Lorecivivint would enter a fragmented osteoarthritis market dominated by inexpensive symptomatic treatments. Its closest commercial competitors would not be only other disease-modifying drugs. Physicians would compare it with corticosteroids, hyaluronic acid, extended-release steroid injections, platelet-rich plasma, physical therapy, oral analgesics, and surgery.
| Competitor class |
Examples |
Competitive advantage |
| Corticosteroid injections |
Triamcinolone acetonide, extended-release triamcinolone |
Low price and rapid symptom relief |
| Hyaluronic acid |
Synvisc, Durolane, Orthovisc |
Established injection use and payer familiarity |
| Oral analgesics |
NSAIDs, acetaminophen |
Low cost and convenience |
| Regenerative procedures |
PRP and cell-based procedures |
Perceived disease modification, despite variable evidence |
| Surgery |
Total knee arthroplasty |
Definitive treatment for advanced disease |
| Other pipeline drugs |
Various intra-articular and systemic candidates |
Potential competition for disease-modifying positioning |
Zilretta, an extended-release triamcinolone product, is an important commercial comparator because it demonstrates that payers and physicians may accept a premium for an intra-articular product with longer symptom relief. Lorecivivint would need to show a more durable benefit, better functional outcomes, or structural preservation to justify substantially higher pricing.
What market size could lorecivivint reach?
The addressable market is large, but the reimbursable market for a premium disease-modifying injection is smaller. Osteoarthritis affects tens of millions of adults in the United States, while knee osteoarthritis represents the main target population for lorecivivint. Only a subset would meet a future label, receive an injection, and obtain payer coverage.
A commercial model using an annual or less-frequent injection produces the following scenarios:
| Scenario |
Treated patients at peak |
Net annual price |
Peak sales |
| Low case |
100,000-150,000 |
$2,000-$3,000 |
$200 million-$450 million |
| Base case |
200,000-350,000 |
$2,500-$3,500 |
$500 million-$1.2 billion |
| High case |
400,000-600,000 |
$3,000-$4,000 |
$1.2 billion-$2.4 billion |
The base case assumes a label covering moderate-to-severe knee osteoarthritis, demonstrated durability of at least six to 12 months, payer coverage after failed conservative therapy, and adoption by orthopedic surgeons, rheumatologists, and sports-medicine specialists.
A label limited to pain reduction without structural or disease-modifying claims would reduce pricing power. If repeat injections were required every three to six months, treatment burden and payer scrutiny would rise. If a single injection produced durable functional improvement and delayed surgery, the product could support a higher price and broader use.
What is the risk-adjusted commercial outlook?
The program’s probability of success is lower than that of a conventional Phase 3 asset because the pivotal evidence has not been consistently positive. A reasonable commercial underwriting framework is:
| Outcome |
Probability-weighted view |
| No approval or program discontinuation |
Material risk |
| Approval with narrow symptomatic label |
Moderate commercial value |
| Approval with durable pain and function claims |
Strong commercial value |
| Approval with credible disease-modifying evidence |
Potential blockbuster profile |
An unadjusted peak-sales range of $500 million to $1.2 billion is reasonable for a successful U.S.-led launch. Applying a development and regulatory probability of approximately 15% to 30% produces a risk-adjusted peak-sales range of roughly $75 million to $360 million. The range would increase if new data resolved the JOINT 1 and JOINT 2 inconsistency.
The principal commercial value drivers are clinical durability, payer willingness to reimburse, injection frequency, differentiation from Zilretta and hyaluronic acid, and the existence of a partner capable of executing orthopedic-market access.
Which companies could challenge or partner on lorecivivint?
Biosplice is the identified developer. No major pharmaceutical commercialization agreement had been publicly disclosed through June 2024.
Potential strategic counterparties would include companies with established orthopedic, specialty-pharmaceutical, or injectable franchises. Relevant commercial capabilities include physician-office distribution, buy-and-bill reimbursement, sterile manufacturing, and payer contracting. The most likely transaction structures would be an ex-U.S. license, a regional commercialization agreement, a co-development deal, or an asset sale.
A partner would likely require clarity on three issues before paying a substantial upfront amount:
- Whether additional pivotal trials are required
- Whether the active patent term extends sufficiently beyond approval
- Whether the product can obtain premium reimbursement over established injections
Key Takeaways
- Lorecivivint is an investigational intra-articular treatment for knee osteoarthritis.
- Biosplice has advanced the program through Phase 3, but JOINT 1 and JOINT 2 produced inconsistent efficacy results.
- The product is not FDA approved and has no Orange Book listing or FDA market exclusivity.
- No publicly disclosed Paragraph IV challenge, patent litigation, or licensing deal had been established through June 2024.
- The base-case peak-sales opportunity is approximately $500 million to $1.2 billion.
- A disease-modifying label and durable annual dosing could support sales above $1.5 billion.
- The primary value risk is regulatory: the program may require additional pivotal evidence before an NDA can be competitively filed.
FAQs
Is lorecivivint available by prescription?
No. Lorecivivint is an investigational drug and is not commercially available by prescription.
Is lorecivivint a biologic or a generic drug?
No. It is a small-molecule drug candidate delivered by intra-articular injection. Biosimilar rules do not apply.
Could lorecivivint replace knee replacement surgery?
No evidence establishes that it can replace total knee arthroplasty. A future approval could support pain relief, functional improvement, or delayed surgery, but those claims would require clinical evidence and FDA authorization.
How does lorecivivint differ from hyaluronic acid injections?
Hyaluronic acid is primarily used for symptomatic treatment and lubrication-related effects. Lorecivivint is designed to modulate disease biology through Wnt-pathway inhibition, although its disease-modifying benefit has not been confirmed by FDA approval.
What would make lorecivivint commercially successful?
The strongest commercial profile would require reproducible Phase 3 efficacy, durable benefit from infrequent dosing, a differentiated safety profile, broad payer coverage, and intellectual-property protection extending well beyond approval.
References
-
Biosplice Therapeutics. (2021). Biosplice Therapeutics announces Phase 3 results for lorecivivint in knee osteoarthritis. Company press materials.
-
ClinicalTrials.gov. (n.d.-a). A study to evaluate the efficacy and safety of lorecivivint in subjects with moderate to severe osteoarthritis of the knee: JOINT 1. U.S. National Library of Medicine. NCT03065246.
-
ClinicalTrials.gov. (n.d.-b). A study to evaluate the efficacy and safety of lorecivivint in subjects with moderate to severe osteoarthritis of the knee: JOINT 2. U.S. National Library of Medicine. NCT03928184.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Center for Drug Evaluation and Research.
-
Samumed. (2020). Samumed changes corporate name to Biosplice Therapeutics. Company announcement.
